Contact Us

Hepatitis B Foundation Welcomes Dr. Robert Gish as Medical Director

Renowned leader in the field of liver disease takes on new role leading advocacy and research
    PHILADELPHIA, PA, February 13, 2014 /24-7PressRelease/ -- The Hepatitis B Foundation (www.hepb.org), the only national nonprofit organization solely dedicated to finding a cure for hepatitis B, is pleased to announce that Robert G. Gish, M.D., became the foundation's medical director on Jan. 30, 2014.

An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has made invaluable contributions to the understanding and treatment of hepatitis B, which is the world's leading cause of liver cancer. A longtime supporter of the foundation's mission and a member of the Scientific Advisory Board, Dr. Gish's new role will further strengthen its research and advocacy efforts worldwide.

"We are delighted to welcome Dr. Gish to our board," said Dr. W. Thomas London, senior member emeritus of Fox Chase Cancer Center and vice president of the board of directors of the Hepatitis B Foundation. "He has long been a leader in the field and has extensive experience in the conduct of clinical trials of new drugs to combat chronic hepatitis B. His leadership as medical director will help us advance the treatment and prevent the severe consequences of this potentially deadly disease."

After receiving his medical degree in 1980, Dr. Gish quickly developed a keen interest in liver health, focusing his research on investigation of viral hepatitis B and C. He went on to become medical director of the liver transplant program at California Pacific Medical Center in 1994, developing an outreach program that eventually served more than 35,000 patients in northern California and Nevada and made the medical center a leading liver transplant center.

Over the course of his career, Dr. Gish has published more than 600 original articles, abstracts and book chapters and more than 120 peer-reviewed publications. Today, he is a clinical professor of Medicine at the University of Nevada in Las Vegas, where he continues to teach, and is a senior consultant at St. Joseph's Medical Center in Phoenix. In 2013, he formed Robert G. Gish Consultants LLC to support liver health and transplant programs with operations, outreach, compliance, financial planning and program development in the U.S. and Asia.

"Dr. Gish's background is a perfect fit for the work we do here at the Foundation and our Baruch S. Blumberg Institute," said Dr. Timothy Block, president of the Hepatitis B Foundation and also a professor of Microbiology at Drexel University. "We are honored that Dr. Gish has agreed to become our medical director and look forward to many years of collaboration so we can finally put an end to this serious liver infection."
To learn more about Dr. Robert Gish, visit his website.

About the Baruch S. Blumberg Institute: The Baruch S. Blumberg Institute was first established in 2003 by the Hepatitis B Foundation to conduct discovery research and nurture translational biotechnology in an environment conducive to interaction, collaboration and focus. The independent, nonprofit research center was renamed in 2013 to honor the man who won the Nobel Prize for his discovery of the hepatitis B virus. To learn more, go to http://www.blumberginstitute.org/.

About the Hepatitis B Foundation: Headquartered in Doylestown, Pa., the Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to http://www.hepb.org, read our blog at http://wp.hepb.org, follow us on Twitter @HepBFoundation, find us on Facebook at http://www.facebook.com/hepbfoundation or call 215-489-4900.


# # #

Read more Press Releases from Rose Strong:


Contact Information


Rose Strong
Furia Rubel Communications

Doylestown, PA
USA
Voice: 215-340-0480
E-Mail: Email Us Here
Website: Visit Our Website

Like This Story?


I like it! 0

Disclaimer


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.